Global Pharmerging Market to Reach $2.20 Billion by 2027 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pharmerging Market Research Report by Product (OTC Drugs and Pharmaceuticals), Indication, Distribution, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Pharmerging Market size was estimated at USD 1,291.23 million in 2021, USD 1,408.34 million in 2022, and is projected to grow at a CAGR 9.32% to reach USD 2,204.54 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Pharmerging to forecast the revenues and analyze the trends in each of the following sub-markets:

• Based on Product, the market was studied across OTC Drugs and Pharmaceuticals. The Pharmaceuticals is further studied across Branded Prescription Drugs and Generic Drugs.
• Based on Indication, the market was studied across Cancer and Autoimmune Diseases and Lifestyle Diseases.
• Based on Distribution, the market was studied across Clinics, Drug Stores Expenditure, E-commerce, and Hospitals.
• Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmerging Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Market Dynamics

Drivers

• Growing elderly population and rising burden of chronic diseases worldwide
• Rising number of private hospitals and healthcare institutes
• Extensive spending on healthcare globally and growing life expectancy among people

Restraints

• High cost of research and development and strict price control

Opportunities

• Potential demand from targeted therapeutics or personalized medicines
• Emerging adoption of pharmerging in developing economies

Challenges

• Concerns over IP protection and socio-politics with complex government approval process

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Pharmerging Market, by Product

7. Pharmerging Market, by Indication

8. Pharmerging Market, by Distribution

9. Americas Pharmerging Market

10. Asia-Pacific Pharmerging Market

11. Europe, Middle East & Africa Pharmerging Market

12. Competitive Landscape

13. Company Usability Profiles

14. Appendix

Companies Mentioned

• Abbott Laboratories Inc.
• AstraZeneca PLC
• Bayer AG
• Beckman Coulter, Inc.
• Bikal Ltd.
• CSL Behring LLC
• Eli Lilly and Company
• Farmson Pharmaceutical Gujarat Pvt. Ltd
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd
• Johnson and Johnson
• Lonza Group AG
• Novartis AG
• Pfizer, Inc.
• Rhombus Pharma Private Limited
• Rochling Group
• SCHOTT AG
• Sun Pharmaceutical Industries Ltd.
• The RSA Group
• ZIM Laboratories Limited

For more information about this report visit https://www.researchandmarkets.com/r/ez1tal

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900